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Leptin reduces adiposity and exerts antisteatotic effects on
nonadipose tissues. However, the mechanisms underlying
leptin effects on lipid metabolism in liver and white adipose
tissue have not been fully clarified. Here, we have studied the
effects of central leptin administration on key enzymes and
transcription factors involved in lipidmetabolism in liver and
epididymal adipose tissue. Intracerebroventricular leptin in-
fusion for 7 d did not change leptin plasma levels but de-
creased triacylglyceride content in liver, epididymal adipose
tissue, and plasma. In both tissues this treatment markedly
decreased the expression of key enzymes of the de novo fatty
acid (FA) synthesis such as acetyl-coenzyme A-carboxylase,
FA synthase, and stearoyl-coenzyme A desaturase-1, in par-
allelwith a reduction inmRNAexpression of sterol regulatory
element binding protein-1c in liver and carbohydrate regu-
latory element binding protein in adipose tissue. In addition,
leptin also decreasedphosphoenol-pyruvate carboxykinase-C
expression in adipose tissue, an enzyme involved in glycero-
neogenesis in this tissue. Central leptin administration down-
regulates delta-6-desaturase expression in liver and adipose
tissue, in parallel with the decrease of the expression of sterol
regulatory element binding protein-1c in liver and peroxi-
some proliferator activated receptor  in adipose tissue. Fi-
nally, leptin treatment, by regulating adipose triglyceride
lipase/hormone sensitive lipase/diacylglycerol transferase 1
expression, also established a new partitioning in the FA-
triacylglyceride cycling in adipose tissue, increasing lipolysis
and probably the FA efflux from this tissue, and favoring in
parallel theFAuptakeandoxidation in the liver.These results
suggest that leptin, acting at central level, exerts tissue-
specific effects in limiting fat tissue mass and lipid accumu-
lation in nonadipose tissues, preventing the development of
obesity and type 2 diabetes. (Endocrinology 148: 5604–5610,
2007)
LEPTIN, A CYTOKINE produced mainly by the whiteadipose tissue (WAT), is actively involved in the con-
trol of body weight and food intake. Dysregulations of leptin
actions are associated with obesity, insulin resistance, and
type 2 diabetes. These facts point to leptin and its actions as
targets of study to clarify these metabolic disorders and
identify potential therapeutic strategies. Several reports have
shown that leptin regulates energy homeostasis by control-
ling peripheral lipid metabolism, and leptin administration
reduces triacylglyceride (TAG) stores and promotes fatty
acid (FA) oxidation in lean and adipose tissues (1–7). There-
fore, it has been postulated that one of the roles of leptin is
to reduce lipid accumulation in nonadipose tissues, prevent-
ing lipotoxicity (8).
In the liver an acute iv leptin infusion decreases liver TAG
secretion, increases hepatic FA oxidation and ketogenesis,
and, as a result, decreases liver TAG levels (9). However, an
acute intracerebroventricular (icv) leptin administration
does not decrease liver TAG levels (9–11). On the other hand,
chronic icv leptin treatment decreases TAG content in liver
and plasma compared with ad libitum fed controls (12), sug-
gesting that leptin, acting at central level, plays an important
role depleting TAG levels in this tissue.
In WAT, the effect of leptin on lipid metabolism has not
been fully characterized and remains controversial. Thus,
adenovirus-induced hyperleptinemia increases the expres-
sion of enzymes of FA oxidation such as acyl-coenzyme A
oxidase and carnitine palmitoyl transferase (CPT)-1, and de-
pletes the TAG without a concomitant increase in the levels
of circulating free FAs (3). This suggests that leptin favored
intracellular FA oxidation in adipocytes. Furthermore, treat-
ment of isolated rat adipocytes with leptin up-regulates the
expression of acyl-coenzyme A oxidase, CPT-1, uncoupling
protein 2, and peroxisome proliferator activated receptor
(PPAR) , all of which are involved in lipid oxidation (13).
In addition, in vivo (14) and in vitro (15) studies indicated a
paracrine/autocrine stimulation of lipolysis in rodent adi-
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pose tissue by leptin, whereas in human adipocytes, in vitro
leptin did not stimulate lipolysis but inhibited the insulin-
induced lipogenesis (16). Other studies suggest that the lep-
tin-induced depletion of WAT is not only due to the mobi-
lization of lipid stores, but also to adipocyte apoptosis (17).
In addition, adipocytes incubated with leptin increase the
oxidation of exogenous, but not of endogenous FAs, and
present a higher TAG breakdown with a concomitant release
of FAs from the cells (13).
Most of the aforementioned studies indicate that lipid me-
tabolism could be regulated directly by leptin acting through
leptin receptors in peripheral tissues. Nevertheless, much ex-
perimental evidence suggests that leptin exerts its effects on
lipid metabolism predominantly through the brain, especially
through the hypothalamic nuclei, in which the leptin receptor
concentration is the highest compared with other tissues (18).
Leptin affects appetite by acting through neuroendocrine path-
ways and autonomic nerves, which transmit leptin signal to the
periphery (19). The relative importance of peripheral vs. central
actions of leptin on metabolic effects of the hormone is not well
characterized and needs further investigation.
In the present study, we have investigated the effects of
centrally administered leptin on the expression of several en-
zymes and transcription factors of lipid metabolism in rat liver
and epididymal WAT (eWAT). The effect of leptin on TAG FA
composition, and stearoyl-coenzyme A desaturase (SCD)-1 and
delta-6-desaturase (D6D) expression in both tissues, is also dis-
cussed. The possible modulation of centrally administered lep-
tin on the insulin action on plasma non-esterified fatty acid
(NEFA) and TAG also has been studied.
Materials and Methods
Animals
The experiments were performed in male, 3-month-old Wistar rats
from our in-house colony (Centre of Molecular Biology, Madrid, Spain).
Animals were housed in climate-controlled quarters with a 12-h light
cycle, and fed ad libitum standard laboratory diet and water. They were
handled according to the European Union laws and the National Insti-
tutes of Health guidelines for animal care. The institutional committee
of bioethics approved the experimental procedures, and special care was
taken to minimize animal suffering and reduce the number of animals
used.
Leptin and insulin administration
The effects of centrally administered leptin on liver and eWAT lipid
metabolism have been performed using three groups of animals ran-
domly distributed: 1) rats infused with leptin, 2) rats infused with vehicle
and allowed to eat ad libitum, and 3) rats infused with vehicle and pair
fed to the amount of food consumed by the leptin-infused animals. icv
leptin administration was performed as described previously (20).
Briefly, rats were anesthetized with ip ketamine/diazepam/atropine
used at 50, 4, and 0.2 mg/kg, respectively (Parke-Davis, Roche and
Braun, Madrid, Spain) and placed in a stereotaxic frame (David Koppf,
Tujunga, CA). An opening in the skull was made with a dental drill at
1.6-mm lateral to the midline and 0.8-mm anterior to bregma. A can-
nula connected to an osmotic pump (Alzet, Palo Alto, CA) was im-
planted in the right lateral cerebral ventricle. Osmotic pumps, with a
releasing rate of 1 l/h, were filled with 0.0082 g/l (0.2 g/d) rat
leptin (Sigma-Aldrich, St. Louis, MO), or its vehicle (PBS). After 7 d the
rats were subjected to an iv insulin (10 IU/kg body weight) (Eli Lilly and
Co., Indianapolis, IN) or saline injection for 30 min and killed by de-
capitation. The liver and eWAT were rapidly dissected for RNA or lipid
assays, or frozen in liquid nitrogen and stored at 70 C until use.
Plasma determinations
Blood samples were withdrawn before and after pump implantation.
Blood samples were centrifuged, and plasma was frozen at 70 C until
use. Plasma leptin and insulin levels were assayed using specific rat kits
from SPI-Bio (Montigny le Bretonneux, France). Triacylglycerol (TAG)
levels were determined by an enzymatic kit from Stanbio Laboratory
(Boerne, TX). Plasma NEFA was measured with an enzymatic kit from
WAKO Chemical (Neuss, Germany). Glycerol was quantified by the
method of Eggstein and Kuhlmann (21), and glucose was determined
using the AmplexRed Glucose/Glucose Oxidase Assay Kit (Molecular
Probes, Inc., Eugene, OR).
Tissue TAG and FA composition measurements
Total lipids were extracted from 100 mg tissue (liver or eWAT) by the
method of Folch et al. (22). Briefly, samples were homogenized in 6 ml
chloroform-methanol (2:1). The mixture stood for 1 h, after which, 1.5 ml
water was added, and the mixture was centrifuged 10 min at 2000  g.
The organic phase was evaporated to dryness under N2 stream and
taken up in chloroform. Fifty microliter aliquots of this organic phase
were solubilized by adding a drop of Triton X-100 as described previ-
ously (5), and total TAG content was determined using the enzymatic
kits from Stanbio Laboratory.
Next, we purified TAG from the total lipids extract using Aminopro-
pyl-bonded (LC-NH2) silica gel cartridges (500-mg matrix) (SUPELCO,
Sigma-Aldrich) according to Bodennec et al. (23). The collected fractions
were again evaporated to dryness under N2 stream. FAs from hepatic
and eWAT TAG were methylated with 5% methanolic HCl. The methyl
esters were analyzed using an Agilent 6890 chromatograph equipped
with flame ionization detection (Agilent Technologies, Inc., Palo Alto,
CA). A fused silica column (length 50 m  internal diameter 0.25 mm)
coated with SGL-1000 phase (0.25-m thickness; Sugerlabor, Madrid,
Spain) was used. The carrier gas was helium, at a flow rate through the
column of 1 ml/min. The temperature of the injector and detector was
set at 250 C and the oven temperature at 210 C. The injection volume was
1 l. FA methyl esters were identified based on the retention times of
known FA standards (Sigma-Aldrich).
RNA extraction and real-time RT-PCR
Total RNA was isolated from liver and eWAT using the TRIzol
reagent (Invitrogen Corp., Carlsbad, CA). The cDNA was synthesized
from 1.5 g DNase-treated RNA using the reverse-transcriptase activity
from Moloney murine leukemia virus (Life Technologies, Inc.-BRL, Pais-
ley, UK), and p[dN]6 (Boehringer Mannheim, Mannheim, Germany) as
a random primer. Relative quantitation of SCD-1, D6D, fatty acid syn-
thase (FAS), acetyl-coenzyme A-carboxylase (ACC)-, diacylglycerol
transferase (DAGT)-1, hormone sensitive lipase (HSL), phosphoenol-
pyruvate carboxykinase (PEPCK)-C, sterol regulatory element binding
protein (SREBP)-1c, carbohydrate regulatory element binding protein
(ChREBP), peroxisomes proliferator activating receptor (PPAR)  and ,
PPAR-coactivator-1 (PGC-1), malonyl-coenzyme A decarboxylase
(MCD), fatty acid transporter (FAT) (FAT/CD36), CPT-1a, and CPT-1b
mRNA expression was performed by TaqMan real-time PCR according
to the manufacturer’s protocol on an ABI PRISM 7500 FAST Sequence
Detection System instrument and software (PE Applied Biosystems,
Foster City, CA), using Pre-Developed TaqMan Assay Reagents (PE
Applied Biosystems). For adipose triglyceride lipase (ATGL), the prim-
ers and probe sets were designed using the manufacturer’s software and
sequences available in GenBank (XM_341960). The probe spanned the
boundary between exons 2 and 3.
To standardize the amount of sample cDNA added to the reaction,
amplification of endogenous control 18S rRNA was included in separate
wells using VIC dye as real-time reporter. The CT method was used
to calculate the relative differences between experimental conditions
and control groups as fold change in gene expression (24).
Statistics
Data are expressed as mean  sem. Statistical analyses were per-
formed using one-way ANOVA (GraphPad Prism version 3.03 software;
GraphPad Software, San Diego, CA), followed by the Tukey test.
Gallardo et al. • Leptin Regulation of Lipid Metabolism Endocrinology, December 2007, 148(12):5604–5610 5605
Results
Biological characteristics of the animals
Before pump implantation, all the animals had similar
body weight and fasting plasma parameters. After 7-d cen-
tral leptin (0.2 g/d) infusion, no differences were found in
plasma leptin levels among the three groups of rats. Leptin-
treated rats showed a 30% reduction in food intake and a 5%
reduction in body weight. Fasting plasma glucose and glyc-
erol levels remained unchanged in the three groups of ani-
mals, whereas plasma insulin decreased significantly in the
leptin-treated rats (Table 1).
Central leptin infusion improves the actions of insulin on
plasma NEFA, and reduces the TAG contents in liver
and eWAT
The main effects of insulin in vivo are the stimulation of glucose
and FA uptake by the periphery, and the reduction of glucose and
TAGoutputbythe liver (25).Euglycemic-hyperinsulinemicclamp
experiments have demonstrated that peripheral (26) or intrahy-
pothalamic leptin infusion (27) increases the whole-body insulin
sensitivityintermsofglucosemetabolism.However, theseauthors
did not detect changes in terms of lipid contents in plasma. Thus,
we first analyzed the effects of icv leptin infusion on the ability of
insulin to regulate plasma lipid content.
The results of Fig. 1 show that central leptin infusion pre-
vented the decrease in plasma NEFA exerted by the reduction
in food intake (Fig. 1A) but decreased the TAG concentrations
compared with the pair-feeding group (Fig. 1B). Upon acute iv
insulin stimulation, in the ad libitum-fed control rats, NEFA
levels were reduced by 25% (Fig. 1, A and C), and TAG contents
decreased by 30% (Fig. 1, B and D). In leptin-treated rats, insulin
did not further reduce the already low levels of plasma TAG.
However, leptin acted synergistically with insulin in decreasing
markedly NEFA levels in plasma (55%) (Fig. 1, A and C).
According to its well-known lipostatic function, central
leptin infusion significantly reduced TAG levels (Fig. 2B) in
eWAT, compared with the vehicle-infused pair-fed group of
rats. In the liver, leptin reduced the hepatic TAG content (Fig.
2A) compared with the vehicle-infused ad libitum-fed rats,
but not to the pair-fed animals.
Central leptin regulates the expression of transcription
factors and key enzymes involved in lipid metabolism in
liver and eWAT
Tables 2 and 3 summarize the effects of central leptin ad-
ministration on different key enzymes and transcription factors
involved in lipid metabolism in liver and eWAT, respectively.
We analyzed the expression of transcription factors involved in
lipid synthesis such as SREBP-1c, ChREBP, or PPAR and the
transcription factors involved in lipid oxidation: PPAR and
PGC-1. As shown in Table 2, SREBP-1c mRNA expression
increased during the pair feeding and was down-regulated by
central leptin treatment in the liver. The same profile was ob-
served with ChREBP mRNA expression in eWAT, with no
effects on SREBP-1c gene expression in this tissue (Table 3).
PPAR mRNA levels were analyzed only in eWAT, in which
it is mainly expressed. Surprisingly, leptin enhanced the up-
regulation of PPAR mRNA levels already stimulated by the
pair feeding in eWAT (Table 3). On the other hand, in liver,
central leptin infusion increased the expression of PPAR and
PGC-1 compared with the pair-feeding group (Table 2),
whereas in eWAT the hormone treatment up-regulated the
mRNA levels of PGC-1 but decreased the PPAR mRNA
expression when compared with the pair-feeding rats (Table 3).
In agreement with the observed changes in hepatic
SREBP-1c expression in liver, central leptin blunted the up-
regulation of the mRNA levels of ACC, FAS, and SCD-1
elicited by the pair feeding (Table 2), suggesting a decrease
in de novo FA synthesis in this tissue of leptin-treated rats.
D6D catalyzes the rate-limiting step in the conversion of
linoleic acid (n6) and -linolenic acid (n3), into arachidonic
acid (n6) and eicosapentaenoic acid (n3), respectively, there-
fore having also an important role in the synthesis of many
molecules involved in cell signaling. As shown in Table 2,
leptin decreases the expression of this key enzyme and coun-
terbalances the up-regulation induced by the decrease in
food intake appreciated in the pair-feeding group.
In eWAT, the effects of centrally administered leptin on the
expression of lipogenic enzymes are similar to those ob-
served in liver. However, in marked contrast to leptin-
mediated hepatic SREBP-1c down-regulation (Table 2), it has
to be pointed out that the reduction on the expression of the
same lipogenic genes as well as that of the glyceroneogenic
enzyme PEPCK-C caused by central leptin occurs without
changes in SREBP-1c expression (Table 3).
We next examined the expression levels of DAGT-1 and
ATGL in eWAT, and we observed that leptin enhanced the
expression of ATGL and DAGT-1 elicited by the pair feeding
in eWAT (Table 3). This, together with a higher expression
of HSL in leptin-treated rats, compared with the ad libitum-
fed controls, suggests an increased basal lipolysis in this
group of animals.
Central leptin infusion up-regulated the mRNA expres-
TABLE 1. Effects of central leptin administration on the biological characteristics of the animals
Treatment SS PF Leptin
Initial body weight (g) 353  10a 372  20a 359  13a
Final body weight (g) 380  13a 359  11b 344  8b
Daily food intake (g) 19  1a 13  1
b
13  1b
Plasma glucose (mM) 6.5  0.8a 5.9  0.4a 5.9  0.6a
Plasma glycerol (mg/dl) 61  5a 59  5a 62  3a
Plasma insulin (ng/ml) 1.6  0.5a 1.4  0.1a 0.7  0.1b
Plasma leptin (ng/ml) 5.9  0.5a 5.4  1a 5.2  0.8a
Body weight and food intake were measured daily during the experiment. After 7-d central leptin (Lep) 0.2 g/d or vehicle vehicle-infused
rats fed ad libitum (SS) or vehicle-infused pair-fed rats (PF) infusion, glucose, glycerol, insulin, and leptin were assessed in plasma. Results
are the mean SEM; n 6–10 rats per group, made in triplicate. Values that do not share the same superscript letter are significantly different
(P  0.05).
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sion of FAT/CD36 in liver (Table 2), but not in eWAT (Table
3), suggesting an increased FA uptake only in liver. In ad-
dition, in both tissues the pair feeding up-regulated the
CPT-1 and MCD mRNA levels (Tables 2 and 3), compared
with the vehicle-infused rats fed ad libitum, and central leptin
augmented this effect.
Effects of central leptin on liver and eWAT TAG FA composition
As previously shown, central leptin infusion down-regu-
lated the mRNA levels of SCD-1 and D6D in liver (Table 2)
and eWAT (Table 3). To determine if these changes in the
expression of both desaturases were reflected in the FA com-
position of TAG in both tissues, TAGs were purified from
total lipid extracts, and their FAs were analyzed by gas
chromatography.
In liver from leptin-treated rats, the TAG FA profile in-
creased its proportion of palmitic and stearic, and decreased
the one of oleic acid (Table 4). Consequently, the SCD-1 index
was reduced. Although the proportion of linoleic acid, the
substrate of D6D, increased, the D6D index did not change
because the proportion of arachidonic acid was also aug-
mented after the leptin treatment when compared with the
pair-fed rats. Interestingly, central leptin infusion for 7 d did
not alter the TAG FA relative abundance in eWAT, in agree-
ment with the lower lipogenic capacity of this tissue com-
pared with the liver.
Discussion
The data presented here demonstrate that icv leptin
infusion exerts tissue-specific effects on the expression of
key enzymes and transcription factors involved in lipid
metabolism in liver and eWAT. As a result, central leptin
affects the TAG FA composition in liver, but not in eWAT.
The fact that plasma leptin does not increase after icv
leptin administration excludes that the observed effects by
this treatment were due to peripheral actions of the hor-
mone. Thus, leptin, acting through hypothalamic neural
circuits and the autonomic nervous system, represses the
expression of genes involved in de novo synthesis of FAs
such as ACC and FAS in both liver and eWAT, which
FIG. 2. Central leptin effects on TAG content in liver and
eWAT. After 7-d central leptin (Lep) 0.2 g/d or vehicle
[vehicle-infused rats fed ad libitum (SS) or vehicle-infused
pair-fed rats (PF)] infusion, TAG content was measured in
liver (A) and eWAT (B). Results are the mean  SEM; n 
10–16 rats per group,made in triplicate. *,P 0.05. **,P
0.01.
FIG. 1. Central leptin infusion improves insulin lowering
effects on plasma NEFA. After 7-d central leptin (Lep) 0.2
g/d or vehicle [vehicle-infused rats fed ad libitum (SS) or
vehicle-infused pair-fed rats (PF)] infusion, rats were in-
jected iv with insulin (INS) (10 IU/kg body weight) or ve-
hicle. At 30 min after injection, plasma NEFA (A) and TAG
(B) were measured. C, Changes in plasma NEFA: percent
respect basal value (after insulin infusion). D, Changes in
plasma TAG: percent respect basal value (after insulin in-
fusion). Results are themean SEM; n 6–8 rats per group,
made in triplicate. *, P  0.05. **, P  0.01.
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agrees well with previous reports in adenovirus-induced
hyperleptinemic rats (1, 2). Central leptin also down-reg-
ulates SCD-1 and D6D mRNA expression in rat liver and
eWAT, when compared with pair-fed animals. In agree-
ment with previously published data (28), our results sug-
gest that by reducing SCD-1 expression, the FA synthesis,
and concomitantly, the synthesis of TAG are probably
decreased. In addition, the up-regulation of CPT-1 by cen-
tral leptin infusion, a key enzyme of -oxidation, may
contribute to reduced hepatic and plasma TAG content.
Although considerable experimental data show that leptin
decreases SCD-1 gene expression and/or enzyme activity (5,
29), there was no evidence reporting the relationship between
leptin and D6D. Most studies on D6D have been performed in
liver (30, 31), whereas data about D6D in WAT have been scarce
(32, 33). Here, we provide evidence for the first time of central
leptin-mediated down-regulation of D6D mRNA expression in
peripheral tissues, such as liver and eWAT.
The expression profiles of ACC, FAS, and SCD-1 parallel the
expression of the lipogenic transcription factors SREBP-1c in
liver and of ChREBP in eWAT, suggesting that central leptin
may impair lipogenesis in liver and eWAT, acting in a tissue-
specific manner, through different lipogenic transcription fac-
tors. In the adipose tissue, ChREBP seems to play an important
role in the regulation of fuel metabolism. Decreased epididymal
fat weight in addition to reduced hepatic lipogenesis was re-
cently reported by Iizuka et al. (34) in the double-deficient mice
ob/ob-ChREBP/. In liver, the decrease in SREBP-1c mRNA
TABLE 2. Changes in mRNA expression in liver after icv leptin treatment using 18S rRNA as the invariant control
Gene SS PF Lep
Transcription factor of lipid synthesis
SREBP-1c 1.0  0.4a 6.4  0.7b 1.1  0.3a
Transcription factors of lipid oxidation
PGC-1 1.0  0.05a 0.5  0.4b 2.0  0.7c
PPAR 1.0  0.2a 3  1b 7  1c
FA de novo synthesis and desaturation
ACC 1.0  0.07a 23.2  0.6b 2.6  0.6c
FAS 1.0  0.1a 12  2b 0.4  0.1c
SCD-1 1.0  0.2a 169  60b 0.5  0.5a
D6D 1.0  0.4a 23  2b 12.8  0.5c
FA uptake and -oxidation
FAT/CD36 1.0  0.2a 0.6  0.2a 2.3  0.2b
CPT-1a 1.0  0.08a 1.4  0.09b 3.1  0.5c
MCD 1.0  0.2a 1.9  0.5a 1.9  0.5a
Values are the means SEM; n 4–6 rats per group, made in triplicate. Values that do not share the same superscript letter are significantly
different (P  0.05, one-way ANOVA followed by Tukey test). Lep, Leptin-infused rats; PF, vehicle-infused pair-fed rats; SS, vehicle-infused
rats fed ad libitum.
TABLE 3. Changes in mRNA expression in eWAT after icv leptin treatment using 18S rRNA as the invariant control
Gene SS PF Lep
Transcription factors of lipid synthesis
SREBP-1c 1.0  0.1a 1.2  0.3a 1.0  0.3a
CHREBP 1.0  0.07a 2.2  0.3b 1.1  0.2a
PPAR 1.0  0.1a 1.7  0.1b 2.6  0.3c
Transcription factors of lipid oxidation
PGC-1 1.0  0.09a 2.0  0.08b 4.0  0.8c
PPAR 1.0  0.05a 1.9  0.3b 1.1  0.05a
FA de novo synthesis and desaturation
ACC 1.0  0.2a 2.9  0.7b 1.3  0.3a
FAS 1.0  0.8a 4  1b 0.4  0.2a
SCD-1 1.0  0.04a 4.1  0.4b 0.3  0.04c
D6D 1.0  0.2a 1.8  0.5b 0.9  0.3a
Glyceroneogenesis
PEPCK-c 1.0  0.2a 1.4  0.1b 1.0  0.08a
FA uptake and -oxidation
FAT/CD36 1.0  0.2a 0.9  0.09a 1.0  0.03a
CPT-1b 1.0  0.1a 2.8  0.5b 5  2c
MCD 1.0  0.05a 1.6  0.1b 2.9  0.2c
Lipolysis and esterification
ATGL 1.0  0.05a 1.3  0.1b 1.9  0.09c
HSL 1.0  0.07a 2.6  0.3b 2.8  0.7b
DAGT-1 1.0  0.08a 1.5  0.2b 2.5  0.2c
Values are the means SEM; n 4–6 rats per group, made in triplicate. Values that do not share the same superscript letter are significantly
different (P  0.05, one-way ANOVA followed by Tukey test). Lep, Leptin-infused rats; PF, vehicle-infused pair-fed rats; SS, vehicle-infused
rats fed ad libitum.
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levels could be mediated by the increased gene expression of
PPAR because the latter has blocked the activity of liver X
receptor on the SREBP-1c promoter, thereby preventing
SREBP-1c transcription (35).
It has been reported that liver D6D mRNA expression can be
activated by SREBP-1c or PPAR, depending on the metabolic
context (32, 36). The pair feeding elicited an up-regulation of
SREBP-1c and PPAR mRNA expression in the liver, which
could respond for the stimulation of the D6D expression under
these conditions. However, central leptin infusion promoted an
increase of hepatic PPAR, but a down-regulation of SREBP-1c
and D6D gene expression compared with the pair-fed rats.
Together, these data suggest that hepatic D6D would be reg-
ulated by central leptin mainly through SREBP-1c. On the other
hand, in eWAT, neither the pair feeding nor central leptin seems
to regulate SREBP-1c mRNA expression, whereas the pattern of
PPAR mRNA expression parallels the expression of D6D,
suggesting that, in this tissue, central leptin regulates D6D gene
expression mainly through PPAR.
Consistent with the SCD-1 and D6D expression data, the
proportion of oleic acid decreases in the TAG FA content in
liver, whereas the relative abundance of linoleic acid in-
creases. Contrasting with the liver, the changes in desaturase
expression do not seem to be reflected in the TAG FA profile
in eWAT. This could be explained by the lower lipogenic
capacity of eWAT compared with the liver. In addition, the
decreased expression of PECK-C in eWAT, an enzyme in-
volved in glyceroneogenesis, and the significant reduction in
lipoprotein lipase activity reported in eWAT after central
leptin administration (12) could reduce the incorporation of
exogenous FA to TAG in this tissue, and then contribute to
explaining the unaltered TAG-FA composition of the eWAT
after the central leptin treatment. Furthermore, central leptin
administration impairs the insulin-stimulated glucose up-
take in eWAT (27) (unpublished observations), which would
also contribute to reducing the glycerol availability and, thus,
de novo TAG synthesis in this tissue.
According to our gene expression data, the lipolysis in
eWAT of leptin-infused rats seems to be mediated by ATGL
and HSL, and the re-esterification by DAGT-1. ATGL is a
triglyceride-specific lipase recently identified, and only stud-
ied in mouse and humans (37, 38). The different substrate
preferences between ATGL and HSL suggest a serial and
coordinated action of these two enzymes in FA store mobi-
lization, with ATGL providing diacylglyceride substrate for
HSL. Although the mechanisms involved in the regulation of
ATGL remain unclear, several studies have shown that the
expression of this protein is sensitive to the nutritional status
of the organism. Thus, ATGL expression is induced in re-
sponse to fasting (39), which agrees with the increased ex-
pression of ATGL mRNA in the eWAT of pair-fed rats. More-
over, our data, which demonstrate an up-regulation of ATGL
in eWAT by central leptin, are consistent with the findings
reported by Villena et al. (39), who showed that ATGL mRNA
levels are very low in obese rodent models, in which leptin
levels are low (ob/ob mice), or the leptin receptor is dysfunc-
tional (db/db mice).
Although we have not directly measured the lipolysis and
glyceroneogenesis in eWAT, according to the gene expres-
sion data reported here, an elevated lipolysis and suppres-
sion of glyceroneogenesis could be the explanation of the
plasma FA levels observed in leptin-treated rats and of the
decrease in eWAT intracellular TAG levels, compared with
the pair-fed group. Moreover, due to the central leptin-
mediated up-regulation of the hepatic FAT/CD36 mRNA
levels, it is tempting to speculate that the FA uptake may be
increased in the liver. Under these conditions, the liver may
play an important role by taking up and oxidizing this extra
NEFA flux, probably released from the eWAT, because in the
leptin-infused rats compared with the pair-fed ones, hepatic
FAT/CD36 and CPT-1 mRNA levels are increased, possibly
through a PPAR-mediated mechanism, as deduced by the
changes in expression of this transcription factor described
here. This, together with a lower expression of ACC, the
enzyme producing malonyl-coenzyme A, in the liver of lep-
tin-treated rats, would favor the FA-oxidation in this tissue.
As a result, intrahepatic TAG levels are reduced by central
leptin treatment.
In conclusion, the results presented here demonstrate that
central leptin administration, by regulating in a different way
the gene expression of some transcription factors such as
SREBP-1c and PPAR, exerts tissue-specific effects on lipid
metabolism in liver and eWAT, and changes the TAG FA com-
position in liver, but not in eWAT. Therefore, it is plausible that
TABLE 4. Central leptin infusion changes the TAG FA relative abundance in liver, but not in eWAT
FA (%)
LIVER WAT
SS PF Leptin SS PF Leptin
14:0 0.6  0.03a 1.0  0.1b 0.6  0.03a 1.4  0.05a 1.5  0.05a 1.4  0.04a
16:0 38  1a 27  2b 40  2a 24  0.3a 25  0.6a 25  0.5a
16:1 3.3  0.3a 4.2  0.8a 2.4  0.1a 6.7  0.2a 7.4  0.5a 5.8  0.5a
18:0 5.6  0.7a 3.7  0.2a,b 8  1a,c 2.7  0.07a 2.6  0.09a 2.8  0.1a
18:1 20  0.7a 39  2b 16  0.3a 30  0.4a 30  0.3a 29  0.2a
18:2 28  0.8a 19  2b 31  2a 31  0.6a 29  1a 33  1a
18:3 1.2  0.1a 0.7  0.1a 1.1  0.1a 1.4  0.05a 1.5  0.04a 1.4  0.04a
20:1 0.2  0.03a 0.5  0.2b 0.2  0.02a 0.2  0.01a 0.2  0.01a 0.2  0.02a
20:4 7.3  0.9a 4.6  0.8b 7  1a 1.0  0.07a 0.9  0.1a 0.9  0.01a
(16:1/16:0)  100 SCD-1 index 10  2a 16  3a,b 6.0  0.5a,c 26  1a 29  1a 24  2a
(20:4/18:2)  100 D6D index 26  6a 26  6a 22  2a 3.3  0.2a 3.2  0.4a 2.9  0.2a
After 7-d central leptin (Lep) 0.2 g/d or vehicle vehicle-infused rats fed ad libitum (SS) or vehicle-infused pair-fed rats (PF) infusion, TAGs
were purified from liver or eWAT total lipid extracts, and TAG FA relative abundance was assessed by gas chromatography. Results are the
mean  SEM; n  6–8 rats per group, made in triplicate. Values that do not share the same superscript letter are significantly different (P 
0.05).
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leptin, acting at a central level, probably leads to the down-
regulation of the de novo lipogenesis in both tissues, increases
lipolysis in eWAT through the ATGL/HSL/DAGT1 pathway
and probably the FA release from this tissue, and promotes a
proportional FA uptake and oxidation mainly in the liver. Nev-
ertheless, these suggestions need further work before a final
conclusion may be drawn.
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